NICE's severity modifiers misalign with public preferences in England & Wales, prioritising health gains at lower disease ...

This blog by Martina Garau (OHE) and Dr. Tina Wang (CIRS) provides a framework to navigate key aims, challenges and opportunities offered by recent initiatives and reflects on future prospects.

Ting (Tina) Wang is Associate Director, HTA Programme and Strategic Partnerships at the Centre for Innovation in Regulatory Science (CIRS). Tina leads CIRS’ work on HTA strategy and research as part ...

Stuart Carroll is a senior health economist and epidemiologist with over 18 years of experience, specialising in infectious diseases and vaccines, market access, health technology appraisal, public ...

Koonal is an associate director in the Science Policy and Research team at the National Institute for Health and Care Excellence. His project portfolio includes overseeing the NICE Listens ...

Matthias is a Senior Economist at OHE and a Visiting Researcher at the Centre for Health Economics & Policy Innovation at Imperial College Business School. His expertise and research interests include ...

https://www.york.ac.uk/che/staff/research/martin-chalkley/ ...

Caroline is a Principal Scientific adviser within the NICE scientific Advice and NICE International teams. She is involved in a range of scientific advice projects and parallel scientific advice ...

Henry joined OHE in October 2024 as a Graduate Economist. He holds an MPharm degree from University College London and is a registered pharmacist with the General Pharmaceutical Council (GPhC). Prior ...

Lou Garrison, PhD, is Professor in the Pharmaceutical Outcomes Research and Policy Program in the School of Pharmacy, and Adjunct Professor in the Departments of Global Health and Health Services at ...

As Vice Provost (Strategic Research Partnerships) at SMU, Dr Cheong develops multi-disciplinary, strategic research partnerships with government and industry, to advance the international standing of ...